TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. TriSalus Life Sciences has set its FY 2025 guidance at EPS.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.35) EPS for the quarter, hitting analysts' consensus estimates of ($0.35). The firm had revenue of $8.26 million for the quarter, compared to analyst estimates of $8.12 million. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
TriSalus Life Sciences Stock Performance
NASDAQ TLSI traded down $0.17 during trading on Thursday, reaching $5.36. 3,658 shares of the company's stock were exchanged, compared to its average volume of 42,948. The company has a 50 day moving average price of $5.44 and a two-hundred day moving average price of $4.75. The stock has a market cap of $163.44 million, a P/E ratio of -2.15 and a beta of 0.48. TriSalus Life Sciences has a 1 year low of $3.22 and a 1 year high of $10.42.
Analyst Upgrades and Downgrades
TLSI has been the subject of a number of research reports. Lake Street Capital began coverage on TriSalus Life Sciences in a research note on Thursday, February 13th. They issued a "buy" rating and a $10.00 price objective for the company. Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences in a research report on Tuesday, December 17th. They issued an "overweight" rating and a $10.00 price target for the company. Canaccord Genuity Group reiterated a "buy" rating and set a $11.00 price target on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Finally, Roth Mkm restated a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $11.56.
Get Our Latest Analysis on TLSI
Insider Buying and Selling
In other TriSalus Life Sciences news, CEO Mary T. Szela acquired 5,030 shares of the firm's stock in a transaction on Wednesday, January 29th. The stock was bought at an average cost of $5.03 per share, for a total transaction of $25,300.90. Following the completion of the purchase, the chief executive officer now directly owns 439,249 shares in the company, valued at $2,209,422.47. This represents a 1.16 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO James Emmett Young purchased 6,000 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was bought at an average price of $5.65 per share, with a total value of $33,900.00. Following the completion of the acquisition, the chief financial officer now owns 30,000 shares in the company, valued at $169,500. This represents a 25.00 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 54,856 shares of company stock valued at $294,608. 32.80% of the stock is currently owned by company insiders.
TriSalus Life Sciences Company Profile
(
Get Free Report)
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Further Reading
Before you consider TriSalus Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.
While TriSalus Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
